In the claims:

1. (Currently Amended) A pharmaceutical composition for intramammary administration to

non-human mammal, comprising an antibacterial agent, prednisolone and a

pharmaceutically acceptable carrier, characterised in that wherein the composition comprises

at least 20 mg of prednisolone / unit dose.

2. (Currently Amended) The composition according to claim 1, characterised in that it

comprises comprising the prednisolone in an amount of 20 to 40 mg / unit dose.

3. (Currently Amended) The composition according to claim 2, characterised in that it

comprises comprising the prednisolone in an amount of 20 to 30 mg/unit dose.

4. (Currently Amended) The composition according to any of claims 1 to 3, characterised in

that claim 1, wherein the antibacterial agent is a cephalosporin.

5. (Currently Amended) The composition according to claim 4, characterised in that

wherein the cephalosporin is cephapirin.

6. (Currently Amended) The composition according to claim 4, characterised in that

wherein the cephalosporin is cefquinome.

7. (Currently Amended) The composition according to any of claims 1 to 6, characterised in

that it comprises claim 1, comprising the antibacterial agent in an amount of 10 to 500 mg/

unit dose.

3

8. (Currently Amended) A process for preparing a pharmaceutical composition as claimed in any of claims 1 to 7 according to claim 1, comprising the steps of mixing an oil and one or more optionally pharmaceutically acceptable additives to form a carrier, and suspending the antibacterial agent and the prednisolone in the carrier.

(Canceled). 9.

Attorney Docket: I-2002.024 US Customer No.: 31846 Express Mail: EV 630722958 US